Currently, there are 212.46M common shares owned by the public and among those 181.48M shares have been available to trade.
The company’s stock has a 5-day price change of -20.27% and 11.61% over the past three months. HIMS shares are trading 48.68% year to date (YTD), with the 12-month market performance up to 152.46% higher. It has a 12-month low price of $11.20 and touched a high of $72.98 over the same period. HIMS has an average intraday trading volume of 19.83 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -24.45%, -3.10%, and 43.48% respectively.
Institutional ownership of Hims & Hers Health Inc (NYSE: HIMS) shares accounts for 73.74% of the company’s 212.46M shares outstanding.
It has a market capitalization of $7.99B and a beta (3y monthly) value of 1.59. The stock’s trailing 12-month PE ratio is 67.22, while the earnings-per-share (ttm) stands at $0.53. The company has a PEG of 2.16 and a Quick Ratio of 1.50 with the debt-to-equity ratio at 0.02. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.33% over the week and 13.75% over the month.
Earnings per share for the fiscal year are expected to increase by 9.43%, and 48.27% over the next financial year. EPS should grow at an annualized rate of 31.05% over the next five years, compared to 17.22% over the past 5-year period.
Looking at the support for the HIMS, a number of firms have released research notes about the stock. Morgan Stanley stated their Equal-Weight rating for the stock in a research note on February 18, 2025, with the firm’s price target at $42-$60. Citigroup coverage for the Hims & Hers Health Inc (HIMS) stock in a research note released on January 10, 2025 offered a Sell rating with a price target of $25. BTIG Research was of a view on January 07, 2025 that the stock is Buy, while Morgan Stanley gave the stock Overweight rating on December 17, 2024, issuing a price target of $42. BofA Securities on their part issued Underperform rating on November 14, 2024.
